Dr. Flemming Ornskov Steps Down as CEO of LifeCycle Pharma in July, 2008. Hereafter Dr. Claus Braestrup Will Act as Executive Chairman

Company Announcement no. 25/2008

To: OMX Nordic Exchange Copenhagen		     Hørsholm, Denmark, June 4, 2008



   Dr. Flemming Ornskov Steps Down as CEO of LifeCycle Pharma in July, 2008. 
Hereafter Dr. Claus Braestrup Will Act as Executive Chairman until a
Replacement 
Has Been Named

Summary: Dr. Flemming Ornskov steps down in July, 2008, as CEO for LifeCycle
Pharma. Hereafter, Dr. Claus Braestrup, current Chairman of the Board of
LifeCycle Pharma, will act as Executive Chairman following the resignation of
Dr. Flemming Ornskov, until a permanent replacement has been identified. 
LifeCycle Pharma A/S (OMX:LCP) announced today that Dr. Flemming Ornskov has
resigned as President and CEO of LifeCycle Pharma in order to join Bausch &
Lomb, the eye health company, as Global President, Pharmaceuticals. He will be
responsible for Bausch & Lomb´s prescription ophthalmic pharmaceuticals and
generics businesses, as well as their general 
eye health and vitamins businesses. Bausch & Lomb is not active in any of
LifeCycle Pharma's therapeutic focus areas. 
The search for a new permanent CEO will be initiated immediately.  Dr. Claus
Braestrup, current Chairman of the Board of LifeCycle Pharma, will act as
Executive Chairman when Dr. Ornskov leaves the Company in July, and until a
permanent replacement has been identified. Dr. Claus Braestrup will as
executive Chairman, after request from the Board of Directors, assume such
specific assignments for the Company, which are necessary to ensure the
Company's continual and uninterrupted business. 
“We regret Dr. Ornskov's decision to leave LifeCycle Pharma. At the same time,
I would like to thank Dr. Ornskov for his very significant contributions to the
Company - initially as Chairman of the Board, and later as CEO. Under his
tenure, LifeCycle Pharma has efficiently built its organization and conducted
an initial public offering as well as a later successful secondary offering,”
said Dr. Braestrup. “Furthermore, during this period, the Company had its first
product, Fenoglide™, approved by the FDA, and launched in the US in February
2008 via our partner, Sciele Pharma. We are currently preparing the initiation
of phase III clinical trials later in 2008 for LCP-Tacro, LifeCycle Pharma's
lead product candidate for organ transplant recipients,” Dr. Braestrup added. 
“I find it extremely difficult to leave LifeCycle Pharma. However, I have
received a once in a lifetime opportunity to join a world renowned company and
global leader in its field. I am encouraged by the fact, though, that I am
leaving LifeCycle Pharma at a time where the Company has a robust pipeline,
strong investor support, and a dynamic and competent management team,” said Dr.
Ornskov. 
Dr. Ornskov will leave LifeCycle Pharma in July, but will be available for one
year on a consulting basis. 

For more information, please contact:
LifeCycle Pharma A/S			LifeCycle Pharma A/S
Dr. Claus Braestrup			Dr. Flemming Ornskov
Chairman of the Board			President and CEO
+45 40 50 80 50 (cell)			+45 24 20 03 68 (cell)

About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceutical company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop
drugs with enhanced absorption and thereby increased bioavailability. LCP has a
cholesterol lowering product, FenoglideTM, currently on the U.S. market and a
diversified near- and medium-term pipeline, including four product candidates
in clinical trials and two in preclinical stages of development. LCP is
listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX:
LCP). For further information, please visit www.lcpharma.com.